Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...
A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
6don MSN
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of ...
6d
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed ...
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 3:10 PM ESTCompany ParticipantsLucas Montarce - Executive VP ...
Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral ...
Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...
Eli Lilly has seen revenue and earnings soar in recent years.
The findings add to competitive pressure on Novo Nordisk’s GLP-1 portfolio and come days after the Danish drugmaker reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results